# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ida B. Wells (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET022-SYN
- Date: 2026-03-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashworth-Banks, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Four weeks after starting dapagliflozin: potassium, creatinine and blood pressure, the losartan dose, and the plan for the months ahead. **S**

## History of present illness

Mrs. Wells returns two weeks after her annual wellness visit and four weeks after starting dapagliflozin. She has had no dizziness, genital itching or sick days. Her home readings average 130/78. Her ankles have not swollen for three weeks and her afternoons are easier, though she still tires on long writing days. Since the kidney education session she has written down her questions about transplant evaluation for her next nephrology visit. She asked for the COVID-19 vaccine today. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 130/78 |
| Side effects | None |
| Symptoms | No ankle swelling; less tired |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Less tired; tires on long writing days |
| Cardiovascular | Negative | No ankle swelling |
| Genitourinary | Negative | No burning or genital itching |
| Neurological | Negative | No dizziness |

4 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet daily **S**
- Dapagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery **S**
- Losartan 100 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/80 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 68.9 kg; BMI 28 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.8 mmol/L; Bicarbonate (total CO2): 23 mmol/L; Urea nitrogen: 31 mg/dL (high); Creatinine: 1.56 mg/dL (high); eGFR, creatinine (CKD-EPI 2021, race-free): 36 mL/min/1.73 m² (low). All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.6 mmol/L at baseline, 4.8 mmol/L at this visit **S**
- Bicarbonate (total CO2): 22 mmol/L at baseline, 23 mmol/L at this visit **S**
- Urea nitrogen: 28 mg/dL (high) at baseline, 31 mg/dL (high) at this visit **S**
- Creatinine: 1.42 mg/dL (high) at baseline, 1.56 mg/dL (high) at this visit **S**
- eGFR, creatinine (CKD-EPI 2021, race-free): 40 mL/min/1.73 m² (low) at baseline, 36 mL/min/1.73 m² (low) at this visit **S**

## Immunizations given today

- COVID-19 vaccine, mRNA, this season **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 132/80, pulse 72; weight 68.9 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3b A2** (N18.32). Potassium 4.8 mmol/L; creatinine 1.56 mg/dL, eGFR 36: about 10% below the first value, the expected effect of losartan and dapagliflozin together and well within the 30% that is accepted. On both medicines as planned. **S**
   - Increase losartan to 100 mg daily, the highest dose, for albuminuria.
   - Potassium and creatinine in two to four weeks.
   - Urine albumin-to-creatinine ratio, hemoglobin, PTH and vitamin D at three months.
   - Nephrology review at three months.
2. **Hypertension with chronic kidney disease** (I12.9). Close to goal: 132/80 in the clinic, 130/78 at home. **S**
   - Losartan increase as above; home readings the week after the change.
3. **Anemia of chronic kidney disease** (D63.1). Tiredness improving; no new bleeding symptoms. **S**
   - Hemoglobin at three months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated cuff, average of two readings) | Every visit | Completed today | 132/80 |
| Self-management | Home blood pressure readings | Seven days to confirm; then the week before each visit while medicines change | Completed today | Average 130/78 |
| Laboratory | Potassium, sodium, bicarbonate, urea nitrogen, creatinine and eGFR | Two to four weeks after starting or increasing an ARB or SGLT2 inhibitor; then with each eGFR check (about twice a year at G3b A2) | Completed today | Four weeks after dapagliflozin: sodium 139, potassium 4.8, bicarbonate 23 mmol/L; urea nitrogen 31, creatinine 1.56 mg/dL; eGFR 36. Repeat two to four weeks after today's losartan increase |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; three to six months after a treatment change; then about twice a year at G3b A2 | Due | Three months after treatment began |
| Medication safety | Medication review: NSAIDs, contrast, dose adjustment, sick-day rules | Every visit | Completed today | No NSAIDs; medicines checked for kidney dosing |
| Medication safety | Medicine safety: dizziness, genital infection, urine volume, sick-day rules | After starting an SGLT2 inhibitor | Completed today | No dizziness, genital infection or sick days |
| Laboratory | Hemoglobin | At least yearly at G3; recheck in three months when mildly low | Due | At three months |
| Laboratory | Calcium, phosphate, intact PTH and 25-hydroxyvitamin D | Baseline at G3; then every 6 to 12 months; vitamin D and PTH three months after starting replacement | Due | PTH and vitamin D at three months on vitamin D3 |
| Medication safety | Vaccines for kidney disease (influenza, pneumococcal, hepatitis B, COVID-19) | Review yearly; hepatitis B series if not immune | Completed today | COVID-19 vaccine today; influenza, PCV20, hepatitis B series, RSV and zoster dose 1 done; zoster dose 2 due in two to six months; hepatitis B antibody check due |
| Referral | Nephrology | When 5-year kidney failure risk is 3 to 5% or more, eGFR falls quickly, or the cause is unclear | Due | Review with Dr. Lindqvist-Moore at three months |

## Goal progress

- Blood pressure below 130/80 mmHg in the clinic and at home within two months of starting treatment, and lower if tolerated. Outcome by 2026-03-03: 132/80 in the clinic and 130/78 at home on losartan 50 mg and dapagliflozin; losartan increased to 100 mg. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% at the three-month check on treatment. Outcome by 2026-03-03: 240 and 228 mg/g at baseline; repeat due at three months on treatment. **S**
- No NSAIDs or other avoidable kidney harms; every medicine checked against her kidney function. Outcome by 2026-03-03: Naproxen stopped at intake; acetaminophen used instead; medicines checked at every visit. **S**
- An informed decision about APOL1 genetic testing, made by her after counseling. Outcome by 2026-01-20: Counseled at the consultation; she chose to defer the test and may ask for it at any time. **S**
- She understands her stage, her risk and the kidney replacement options, and her wishes are recorded, long before any decision is needed. Outcome by 2026-02-17: Kidney education session completed; wishes recorded at the annual wellness visit. **S**

## Medication changes

- Stopped: Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating **S**
- Started: Losartan 100 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026), Aether Forge
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Potassium and creatinine in two to four weeks. Review with the urine albumin, hemoglobin, PTH and vitamin D in three months, and nephrology review then. Call for dizziness, vomiting or diarrhea (hold losartan and dapagliflozin that day), or swelling of the lips or tongue (call 911). **S**

